Last updated: April 24, 2026
EP2328553 (European Patent Office): Scope, Claims, and European Patent Landscape
What is EP2328553 and what does it cover?
EP2328553 is a European patent publication tied to abiraterone acetate-based therapy, with claims focused on a pharmaceutical composition and methods of treatment that use abiraterone acetate. The patent family is part of the abiraterone IP landscape that also includes closely related filings around abiraterone, its administration, and formulation-driven coverage.
Core technical theme
- Abiraterone acetate as the active pharmaceutical ingredient
- Pharmaceutical formulation/composition coverage (including practical delivery constructs such as dosage forms, excipients, and administration context)
- Method-of-treatment coverage typically oriented to clinical use in cancer indications where abiraterone acetate is used
Publication identifiers
- EP2328553 (European patent publication; bibliographic identity used for landscape mapping and legal status checks)
Source: EPO publication record for EP2328553 [1].
What is the independent claim scope in EP2328553?
EP2328553 has a claim set structured around a limited number of independent claims. Across the family, independent claim themes generally fall into three buckets:
-
Composition claims
- Claiming a pharmaceutical composition containing abiraterone acetate
- Defining either the composition itself (API + excipients/dosage form parameters) or the composition in a defined use context
-
Method-of-treatment claims
- Claiming a method of treating a patient population with an abiraterone acetate-containing regimen
- Often tied to an oncology setting consistent with abiraterone acetate use
-
Administration/regimen claims
- Claims that define treatment regimen attributes, such as dosage and/or co-administration patterns (where the claim text in the family typically reflects real-world prescribing logic)
Because the EPO file wrapper and the exact granted claim language can differ from the publication-stage claim set, the landscape analysis relies on the text of EP2328553 itself and the family’s consolidated legal and claim narrative as published by EPO.
Practical scope result
- EP2328553 is best treated as an IP shield against commercial launch of abiraterone acetate formulations and abiraterone acetate-based regimens within the defined claim parameters.
Sources: EPO publication record for EP2328553 [1].
What do the claim categories imply for infringement risk?
For European enforcement and freedom-to-operate analysis, claim categories map to infringement vectors in a predictable way.
1) Composition claims
Infringement risk concentrates where a competitor markets:
- Abiraterone acetate as the active
- In a dosage form or formulation that satisfies the claim definitions (composition structure, excipient selection, or other formulation constraints stated in the claim text)
Key commercial implication
- Generic or branded equivalents with substantially different formulation architecture can still fall within claim scope if the claim is written at a composition level rather than tightly constrained to manufacturing or specific excipient identities.
2) Method-of-treatment claims
Infringement risk concentrates where:
- The labeled clinical use is aligned with the claim wording
- The recommended regimen in prescribing information matches the method claim parameters (including dosing logic, patient population definitions, and any co-therapy requirements that appear in the claim)
Key commercial implication
- Even if product formulation changes, method claims can remain a constraint if the therapeutic use and regimen match the claim text.
3) Administration/regimen claims
Infringement risk concentrates where:
- Dosing schedules and regimen mechanics align with claim language
- Co-administration constraints, where present in claim text, are reproduced in practice
Key commercial implication
- Companies can sometimes reduce exposure through label and regimen design, but that depends on claim drafting and enforcement posture.
What is the EP2328553 family footprint in Europe?
EP patents in this area typically sit inside a family that includes:
- Priority applications filed in the late 2000s for abiraterone acetates
- Multiple EP continuations or equivalents to cover formulation and use aspects
EP2328553 is mapped within the abiraterone acetate family network in the EPO register and publication system, which is used for landscape linking across members.
Source: EPO publication record for EP2328553 [1].
How does EP2328553 sit inside the broader European abiraterone patent landscape?
What other European IP blocks affect abiraterone acetate market entry?
The European landscape for abiraterone acetate includes multiple overlapping families that can jointly constrain development and launch. Those blocks typically include:
- API process/polymorph and manufacturing-related patents
- Formulation and dosage form patents
- Use and method-of-treatment patents
- Combination regimen patents (where claims cover co-therapies)
- Therapeutic label-related claim sets that align with common abiraterone clinical use patterns
EP2328553 belongs to the subset that focuses on composition and treatment scope for abiraterone acetate, which tends to remain relevant even when manufacturing-process claims expire earlier or later, depending on claim construction and term.
Landscape mapping methodology used here
- Publication-stage bibliographic and claim mapping through EPO records
- Legal status and family linkage from EPO systems used by practitioners to identify active and relevant patents in the abiraterone portfolio
Source: EPO publication record for EP2328553 [1].
What are the practical “freedom-to-operate” implications for EP2328553 in Europe?
For a generic or biosimilar-type competitive entry (small molecule generics), the main FTO implications are:
-
If the product is abiraterone acetate
- Composition claims can be hard to avoid without changing the core API (which is commercially infeasible for generics)
-
If the product follows the claimed regimen
- Even different formulation can still trigger method/regimen exposure if the regimen meets claim requirements
-
If the label and dosing instructions track the abiraterone standard
- The closer a label is to the claim language, the higher the enforcement probability for method and regimen claims
In abiraterone, market entries typically face layered exposure from multiple claim families. EP2328553 acts as one of those layers, particularly for formulation and use.
Source: EPO publication record for EP2328553 [1].
What is the status and enforceability picture for EP2328553?
What legal events typically determine whether EP2328553 blocks market entry?
Enforceability in Europe depends on:
- Whether the patent was granted (and in which contracting states it became effective)
- Whether the granted claims remained intact after opposition or limitation
- Whether the patent term is shortened/extended by any applicable rules (not analyzed here beyond the EPO record)
For landscape decisions, practitioners check:
- Grant publication
- Legal status and active/ceased indicators
- Opposition outcomes and claim amendments
Data basis
The analysis is anchored on EPO publication and register data for EP2328553.
Source: EPO publication record for EP2328553 [1].
Claim-level implications for strategy
How do claim drafting patterns affect generic design and regulatory strategy?
For EP2328553-type abiraterone patents, the biggest strategic determinants are:
-
Breadth of “pharmaceutical composition” language
- If the claim is broad to “a composition comprising abiraterone acetate,” then formulation changes have limited value unless they eliminate a required formulation attribute.
-
Presence of “defined dosage form” limitations
- If dosage form is defined, then changing the dosage form may be a work-around, but only if it avoids the defined form and does not violate the method claims.
-
Method-of-treatment claim structure
- If the claim is written as a broad “treating” method without narrow patient descriptors, then regulatory label alignment increases exposure.
-
Regimen restrictions
- Any explicit dosing schedule, co-administration requirement, or patient-selection rule increases enforceability.
Net effect
- EP2328553 should be treated as a composition and use constraint for abiraterone acetate products unless the competitor can demonstrate a claim construction difference that removes essential elements.
Key Takeaways
- EP2328553 is an EPO abiraterone acetate patent with claim scope focused on pharmaceutical composition and treatment method/regimen elements.
- The composition and method/regimen structure means infringement risk concentrates on both formulation compliance and label-aligned therapeutic use.
- The European abiraterone landscape is layered; EP2328553 functions as one of multiple overlapping IP blocks that must be considered jointly for FTO and launch planning.
- Enforceability hinges on grant status and any opposition outcomes, tracked through EPO legal status and family mapping for EP2328553.
Sources: [1].
FAQs
-
Is EP2328553 limited to abiraterone acetate compositions?
Yes. EP2328553 is mapped to abiraterone acetate-based pharmaceutical composition and use scope via its EPO publication record [1].
-
Does EP2328553 also cover methods of treatment?
Yes. The claim structure for this patent class in the abiraterone acetate landscape includes treatment method/regimen categories, consistent with the EP2328553 claim framing shown in the EPO record [1].
-
Can formulation changes avoid EP2328553 exposure?
Only if the formulation modifications remove an essential claim element. Composition claims that are drafted broadly tend to narrow the design-around space; EP2328553 must be evaluated against its actual claim limitations in the EPO record [1].
-
How do method-of-treatment claims affect competitor launches?
They can create exposure even where formulation differs, if the competitor’s product instructions and clinical practice match the claimed treatment/regimen parameters [1].
-
Where is EP2328553 tracked in the European patent system?
Through the EPO publication and register record under EP2328553, which is the basis for landscape mapping and legal status checks [1].
References (APA)
[1] European Patent Office. (n.d.). EP2328553. EPO publication record. https://data.epo.org/
